Accordingly, targeting epigenetic mechanisms responsible for the low/absent PD-L1 expression on cancer cells has emerged as an attractive strategy to improve efficacy of PD-1-directed immunotherapies in selected patient cohorts ([12]). This evidence concerns the gene PDCD1 and cancer.